Long-term effect of azithromycin in bronchiolitis obliterans syndrome
Authors:
Open Access
- 15 October 2019
- journal article
- research article
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 6 (1) , e000465
Abstract
Introduction: Azithromycin stabilises and improves lung function forced expiratory volume in one second (FEV1) in lung transplantation patients with bronchiolitis obliterans syndrome (BOS). A post hoc analysis was performed to assess the long-term effect of azithromycin on FEV1, BOS progression and survival . Methods: Eligible patients recruited for the initial randomised placebo-controlled trial received open-label azithromycin after 3 months and were followed up until 6 years after inclusion (n=45) to assess FEV1, BOS free progression and overall survival. Results: FEV1 in the placebo group improved after open-label azithromycin and was comparable with the treatment group by 6 months. FEV1 decreased after 1 and 5 years and was not different between groups. Patients (n=18) with rapid progression of BOS underwent total lymphoid irradiation (TLI). Progression-free survival (log-rank test p=0.40) and overall survival (log-rank test p=0.28) were comparable. Survival of patients with early BOS was similar to late-onset BOS (log-rank test p=0.74). Discussion: Long-term treatment with azithromycin slows down the progression of BOS, although the effect of TLI may affect the observed attenuation of FEV1 decline. BOS progression and long-term survival were not affected by randomisation to the placebo group, given the early cross-over to azithromycin and possibly due to TLI in case of further progression. Performing randomised placebo-controlled trials in lung transplantation patients with BOS with a blinded trial duration is feasible, effective and safe.Keywords
This publication has 16 references indexed in Scilit:
- Prophylactic Azithromycin Therapy After Lung Transplantation: Post hoc Analysis of a Randomized Controlled TrialAmerican Journal of Transplantation, 2016
- Azithromycin improves lung function in patients with post‐lung transplant bronchiolitis obliterans syndrome: a meta‐analysisClinical Transplantation, 2014
- The Registry of the International Society for Heart and Lung Transplantation: 29th Adult Lung and Heart-Lung Transplant Report—2012The Journal of Heart and Lung Transplantation, 2012
- A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantationEuropean Respiratory Journal, 2010
- Azithromycin is associated with increased survival in lung transplant recipients with bronchiolitis obliterans syndromeThe Journal of Heart and Lung Transplantation, 2010
- Course of FEV1 after Onset of Bronchiolitis Obliterans Syndrome in Lung Transplant RecipientsAmerican Journal of Respiratory and Critical Care Medicine, 2007
- Azithromycin Reverses Airflow Obstruction in Established Bronchiolitis Obliterans SyndromeAmerican Journal of Respiratory and Critical Care Medicine, 2005
- Long-Term Azithromycin Use for Treatment of Bronchiolitis Obliterans Syndrome in Lung Transplant RecipientsThe Journal of Heart and Lung Transplantation, 2005
- AZITHROMYCIN THERAPY FOR PATIENTS WITH BRONCHIOLITIS OBLITERANS SYNDROME AFTER LUNG TRANSPLANTATIONTransplantation, 2004
- Lung TransplantationNew England Journal of Medicine, 1999